Timeline of key events in the development of Campath

The drug dramatically improves the patient's condition.1991-01-01T00:00:00+0000BTG starts negotiations to license Campath to a commercial partner.1993-01-01T00:00:00+0000Waldmann takes up a position in the William Dunn School of Pathology, 1994-01-01T00:00:00+0000The move is prompted by Waldmann's Oxford University appointment.1994-01-01T00:00:00+0000Coles joins as a doctoral student.1994-01-01T00:00:00+0000This is due to the company being reabsorbed into its parent company and disappointing results from trials conducted with Campath-1H for RA.1994-10-01T00:00:00+0000Roy Calne, Peter Friend and Waldman's team launch a small trial with 31 kidney transplant patients to see if Campath-1H can help in reducing immunosuppressant drugs. 1997-01-01T00:00:00+0000Wellcome transfers its manufacturing expertise on Campath to Boehringer Ingelheim. 1997-01-01T00:00:00+0000LeukoSite is granted the license by BTG to develop Campath-1H for CLL and other disease indications.1997-04-01T00:00:00+0000The two companies enter a drug development partnership. 1997-05-01T00:00:00+0000Leukosite raises US$17 million.1997-08-01T00:00:00+0000Analysis of 29 MS patients given MS indicate Campath-1H might be more effective if given earlier in the course of the disease.1998-01-01T00:00:00+0000The trial is to test Campath-1H for treating B-CLL. 1998-04-01T00:00:00+0000Results collected from 93 patients indicates Campath-1H to be a promising treatment for B-CLL.1999-06-01T00:00:00+0000The alliance is for the marketing of Campath-1H.1999-08-01T00:00:00+0000Millennium Pharmaceuticals pays US$750 million in stock.1999-12-01T00:00:00+0000An application is submitted. 1999-12-01T00:00:00+0000Known as the CAM 307 trial, the study compareds Campath-1H with chlorambucil, a standard first-line treatment for the disease.2001-01-01T00:00:00+0000The approval is for Campath-1H to be used as a third-line treatment of B-CLL.2001-05-01T00:00:00+0000Campath-1H is approved for the European market as a third-line treatment of B-CLL. 2001-07-01T00:00:00+0000
Date Event People Places
1991The first MS patient is given Campath-1HWaldmann, hale, CompstonCambridge University
1993The rights to Campath are assigned to the British Technology Group (BTG).WaldmannCambridge University
1 Jan 1994Waldmann moves to Oxford University.WaldmannOxford University
1994The TAC relocates to Oxford.Hale, WaldmannOxford University
1994Alasdair Coles joins Compston's teamColesCambridge University
October 1994Wellcome Biotech abandons development of Campath-1H.Wellcome Biotech
1997Small scale tests launched with Campath-1H for organ transplant patients.Waldmann, Calne, FriendCambridge University
1997LeukoSite enters a manufacturing agreement for Campath-1H with Boehringer Ingelheim.Leukosite, Boehringer Ingelheim
April 1997Christopher Mirabelli, Chief Executive Officer of LeukoSite, agrees to take over the commercial development of Campath-1H.MirabelliLeukoSite
May 1997LeukoSite partners with Ilex Oncology.LeukoSite, Ilex Oncology
1 Aug 1997Leukosite makes its first initial public offering.Leukosite
1998Analysis of 29 MS patients given MS indicate Campath-1H might be more effective if given earlier in the course of the disease.Compston, Coles, Waldmann, HaleCambridge University
1 Apr 1998Leukosite and Ilex Oncology launch their first joint clinical trial of Campath-1H.Leukosite, Ilex Oncology
1 Jun 1999Results collected from 93 patients indicates Campath-1H to be a promising treatment for B-CLL.LeukoSite, Ilex Oncology
August 1999LeukoSite and Ilex Oncology partner with Schering AG.Leukosite, Ilex Oncology, Schering AG
1 Dec 1999Millennium Pharmaceuticals acquires LeukoSite.Millennium Pharmaceuticals, Leukosite
1 Dec 1999Regulatory approval is sought for Campath-1H for the treatment of B-CLL.Millennium Pharmaceuticals, Ilex Oncology
2001 - 2004Trial to establish efficacy of Campath-1H as first-line treatment for B-CLL.Genzyme
1 May 2001FDA approved Campath-1H 
1 Jul 2001European approval granted for Campath-1H 

1991

The first MS patient is given Campath-1H

1993

The rights to Campath are assigned to the British Technology Group (BTG).

1993

Waldmann moves to Oxford University.

1994

The TAC relocates to Oxford.

1994

Alasdair Coles joins Compston's team

Oct 1994

Wellcome Biotech abandons development of Campath-1H.

1997

Small scale tests launched with Campath-1H for organ transplant patients.

1997

LeukoSite enters a manufacturing agreement for Campath-1H with Boehringer Ingelheim.

Apr 1997

Christopher Mirabelli, Chief Executive Officer of LeukoSite, agrees to take over the commercial development of Campath-1H.

May 1997

LeukoSite partners with Ilex Oncology.

May 1997

Leukosite makes its first initial public offering.

1998

Analysis of 29 MS patients given MS indicate Campath-1H might be more effective if given earlier in the course of the disease.

1998

Leukosite and Ilex Oncology launch their first joint clinical trial of Campath-1H.

1998

Results collected from 93 patients indicates Campath-1H to be a promising treatment for B-CLL.

Aug 1999

LeukoSite and Ilex Oncology partner with Schering AG.

Aug 1999

Millennium Pharmaceuticals acquires LeukoSite.

Aug 1999

Regulatory approval is sought for Campath-1H for the treatment of B-CLL.

2001 - 2004

Trial to establish efficacy of Campath-1H as first-line treatment for B-CLL.

2001

FDA approved Campath-1H

2001

European approval granted for Campath-1H